Dr Adam Scheiner, a World-Renowned Surgeon Focuses on RESET for Festoons, RESET for Upper Lids, and RESET for Full Face Laser Procedures

Dr. Adam Scheiner establishes solo practice focused on rejuvenating the eyes, face and resetting the clock

World-renowned eyelid and facial cosmetic surgeon Dr Adam Scheiner has opened a new, solo practice.

Establishing a solo cosmetic laser surgery practice represents the next chapter in Dr. Scheiner’s groundbreaking career. After two decades of delivering patient rejuvenations as a valued partner of Tampa Eye Clinic’s physician team, Dr. Scheiner says, “It’s time to take the next step and focus on delivering my innovative RESET ® procedures in a setting that’s dedicated to patient transformations.”

Dr Adam Scheiner is the only physician in the world to offer RESET, his proprietary advanced deep resurfacing procedures. These surgeries go beyond reducing signs of aging: they reset the skin and restore the patient’s eyes to their appearance from years earlier.

Dr. Scheiner’s new practice is in Tampa, Florida, where he has been treating patients from around the world for 25 years. RESET for Festoons is his signature surgery, offering the only real solution for a condition that others refuse to treat or mistreat, often making Festoons look worse. He also uses advanced lasers for full face rejuvenation, and recently perfected RESET for Upper Eyelids, a procedure that resurfaces eyelid skin after blepharoplasty, tightening and smoothing this delicate skin.

Dr Adam Scheiner said

“Practicing on my own with a complete focus on cosmetic patients has been a goal for a long time. My team and I are excited about concentrating on providing RESET ® procedures for eyelid and facial transformations. I’m also hoping to continue developing innovative, transformative procedures.”

All three RESET surgeries offer natural results that turn back the clock by decades, reducing the signs of aging and resetting the skin’s age.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”